SCHEMBL3878433

SCHEMBL3878433

O=C1OCCN1c1ccc(-c2nc3c(s2)CCN(C2=CC=C2)CC3)cc1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TNKS O95271 1/20 0.38
NPC1 O15118 4/20 0.34
RAB9A P51151 4/20 0.34
KMT2A Q03164 2/20 0.33
CCNC P24863 2/20 0.32
CDK8 P49336 2/20 0.32
OGA O60502 1/20 0.32
F10 P00742 1/20 0.32
PKM P14618 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
BCL2 P10415 1/20 0.30
BECN1 Q14457 1/20 0.30
DPP4 P27487 2/20 0.30
DPP8 Q6V1X1 2/20 0.30
DPP9 Q86TI2 2/20 0.30
DPP7 Q9UHL4 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3879284 0.83 IP6K1 (0.37) NPC1RAB9AKMT2APKMSMN1; SMN2
SCHEMBL3881648 0.83 APP (0.42) NPC1RAB9AKMT2AOGASMN1; SMN2
SCHEMBL3882033 0.82 NPC1 (0.34) NPC1RAB9AKMT2APKMSMN1; SMN2
SCHEMBL3882292 0.82 NPC1 (0.36) NPC1RAB9AKMT2APKMSMN1; SMN2
SCHEMBL3878427 0.80 HRH3 (0.46) TNKSNPC1RAB9AKMT2ACCNC
SCHEMBL3879666 0.78 RAB9A (0.38) NPC1RAB9AKMT2AOGASMN1; SMN2
SCHEMBL3880644 0.78 NPC1 (0.50) NPC1RAB9AKMT2ASMN1; SMN2NPSR1
SCHEMBL3879819 0.76 RAB9A (0.42) NPC1RAB9AKMT2APKMSMN1; SMN2
SCHEMBL3879972 0.75 RAB9A (0.39) NPC1RAB9AKMT2AF10SMN1; SMN2
SCHEMBL3880047 0.75 DPP4 (0.43) NPC1RAB9AKMT2AOGASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1858900-B1 FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR GLAXO GROUP LTD (GB) 2009-01-07 EP claimed
US-20080161289-A1 Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor GLAXO GROUP LIMITED 2008-07-03 US claimed
EP-1858900-B1 FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR GLAXO GROUP LTD (GB) 2009-01-07 EP disclosed
US-20080161289-A1 Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor GLAXO GROUP LIMITED 2008-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161289-A1 Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor HRH3, HRH4, HRH2 TNKS 3378/4885NPC1 1741/4885RAB9A 2125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.